Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Adv Mater. 2016 Oct 31;29(1):10.1002/adma.201603276. doi: 10.1002/adma.201603276

Figure 4.

Figure 4

In vivo NIR imaging and antitumor effect of PEGylated BP NSs. (a) Time-lapse NIR bio-imaging of nude mice. The tumors were circled with a red-dotted line. G1: BP-PEG/Cy7 NSs group; G2: BP-PEG-FA/Cy7 NSs group. (b) NIR bio-imaging of major organs and tumors after i.v. injection at 24 h. H: Heart; LI: Liver; S: Spleen; LU; Lung; K: Kidney; T: Tumor. (c) Semi-quantitative biodistribution of BP-PEG/Cy7 NSs and BP-PEG-FA/Cy7 NSs in nude mice measured by the averaged fluorescence intensity of organs and tumors. (d) Inhibition of HeLa tumor growth after different treatments (* P < 0.05, ** P < 0.01). Group 1: Saline; Group 2: CQ; Group 3: DOX; Group 4: BP-PEG-FA/DOX; Group 5: BP-PEG-FA + NIR; Group 6: BP-PEG-FA + NIR + CQ; Group 7: BP-PEG-FA/DOX + NIR + CQ. (e) Morphology of tumors removed from the sacrificed mice in all groups at the end point of study. (f) H&E stained histological images of tissue sections from major organs after 14 days of treatment with BP-PEG-FA NSs, BP-PEG-FA NSs + CQ, and BP-PEG-FA/DOX NSs + CQ. Saline was used as a control.